stoxline Quote Chart Rank Option Currency Glossary
Sarepta Therapeutics, Inc. (SRPT)
123.8325  7.583 (6.52%)    05-30 15:48
Open: 122.95
High: 125.725
Volume: 3,551,643
Pre. Close: 116.25
Low: 120.23
Market Cap: 11,705(M)
Technical analysis
2024-05-30 3:17:37 PM
Short term     
Mid term     
Targets 6-month :  154.91 1-year :  171.32
Resists First :  132.63 Second :  146.67
Pivot price 127.79
Supports First :  109.91 Second :  91.44
MAs MA(5) :  120.72 MA(20) :  129.24
MA(100) :  125.23 MA(250) :  114.12
MACD MACD :  -1.8 Signal :  -0.1
%K %D K(14,3) :  29 D(3) :  15.3
RSI RSI(14): 45.2
52-week High :  146.67 Low :  55.25
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ SRPT ] has closed above bottom band by 31.7%. Bollinger Bands are 26.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 117.34 - 118.11 118.11 - 118.82
Low: 110.5 - 111.48 111.48 - 112.36
Close: 114.72 - 116.28 116.28 - 117.69
Company Description

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Headline News

Thu, 30 May 2024
Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap Down to $123.46 - Defense World

Wed, 29 May 2024
When Will Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Turn A Profit? - Yahoo Movies UK

Wed, 29 May 2024
Sarepta Therapeutics Set to Join S&P MidCap 400 - Yahoo Finance

Wed, 29 May 2024
Is Sarepta Therapeutics, Inc. (NASDAQ:SRPT) A Good Fast Growth Stock To Buy? - Yahoo Finance

Tue, 28 May 2024
Why Is Sarepta Therapeutics Stock Trading Lower On Tuesday? - Sarepta Therapeutics (NASDAQ:SRPT) - Benzinga

Tue, 28 May 2024
RBC Capital cuts Sarepta to sector perform ahead of FDA decision (NASDAQ:SRPT) - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 95 (M)
Shares Float 90 (M)
Held by Insiders 4.4 (%)
Held by Institutions 87.4 (%)
Shares Short 5,690 (K)
Shares Short P.Month 4,600 (K)
Stock Financials
EPS 0.43
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 10.17
Profit Margin 1.2 %
Operating Margin 8.4 %
Return on Assets (ttm) -1.9 %
Return on Equity (ttm) 2 %
Qtrly Rev. Growth 63 %
Gross Profit (p.s.) 0
Sales Per Share 14.81
EBITDA (p.s.) -0.57
Qtrly Earnings Growth 0 %
Operating Cash Flow -534 (M)
Levered Free Cash Flow -367 (M)
Stock Valuations
PE Ratio 280.61
PEG Ratio 0.3
Price to Book value 12.14
Price to Sales 8.33
Price to Cash Flow -21.87
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android